1.0 semaglutide Many people start and stop GLP-1s. Here's why that may be a bad idea : NPR Novo Nordisk and Hims &

There also may not be enough information yet for groups that scientists are just now beginning to study in clinical trials like adolescents with type 2 diabetes or obesity, though the FDA has already approved several GLP-1 agonists for these groups (14,15)

Prescriptions to young people for two GLP-1 medications semaglutide and liraglutide (Saxenda) jumped 700% between 2022 and 2024

Additional information Enhanced Digital Features To view enhanced digital features for this article go to Electronic supplementary material Below is the link to the electronic supplementary material

RESCU/FAQ MEDICAL WEIGHT LOSS LONGEVITY GLP-1 & Peptides Questions, answered